Drug Profile
Orbofiban
Alternative Names: CS 511; SC 57099BLatest Information Update: 13 May 2008
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Daiichi Sankyo Company; Pfizer
- Class Antiplatelets; Esters; Pyrrolidines; Small molecules
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Thrombosis; Unstable angina pectoris
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 09 Jun 2000 A substudy of the OPUS-TIMI 16 trial has been added to the adverse events and Ischaemic Heart Disease and Thromboses therapeutic trials sections